If cancer- and chemotherapy-induced reduction of DNM1 is truly linked with the long-term neurodegenerative consequences culminating into cognitive impairments, replacement of DNM1 may be another viable therapeutic strategy for ameliorating CRCI. The gene discussed is DNM1; the disease is cancer.